Topical estradiol delivers hormone to the scalp with less systemic exposure, but evidence is thin and it is still a hormone. It needs a doctor's supervision, and people with estrogen-sensitive cancers must not use it without medical approval.
Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
There is no completed human trial of GHK-Cu for androgenetic alopecia, so it cannot be compared with minoxidil or finasteride on evidence; clinics and community users treat it as an unproven add-on, not a replacement.
Oral tofacitinib acts on immune signalling throughout the body and has the stronger regrowth evidence in alopecia areata, alongside an FDA boxed warning; topical tofacitinib aims to act only on the scalp, but the human evidence is a handful of small compounded-formulation studies with no large randomized trial. Neither route is approved for hair loss, and regrowth generally reverses after treatment stops.
Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.
Finasteride is more effective than saw palmetto in reducing DHT levels.
Studies and the drug label report that finasteride's benefit lasts only while it is taken: after stopping, scalp DHT returns to baseline and hair loss resumes over roughly 6 to 12 months. Stopping a prescription drug is a decision to make with the prescriber.
Stemoxydine may help improve hair density in early-stage thinning and alopecia.
There is no published human trial of topical bicalutamide for hair loss, and no licensed topical product exists, so it cannot be called safer than finasteride — or shown to work at all. Oral finasteride has decades of trial data with a documented side-effect profile, and topical finasteride has a phase III trial behind it.
Topical cetirizine is not an approved product and its use for female-pattern hair loss is off-label. The evidence is one small unblinded pilot study in mixed-sex patients and one randomized trial in 66 women where cetirizine was added to minoxidil; it is unproven on its own.
GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.
Minoxidil stimulates hair growth, while finasteride reduces DHT levels to prevent hair loss.
Reported hair regrowth with tofacitinib comes from alopecia areata, an autoimmune condition — mostly from small, non-randomized studies, with relapse common after stopping. There is no good evidence it helps pattern hair loss, and it is not approved for hair loss anywhere.
TDM-105795 is still in development and not yet available for consumers.
Pumpkin seed oil may help block DHT, potentially reducing hair loss.
Clinics commonly prescribe a short course of antibiotics and pain relief after a transplant, and some recommend minoxidil or finasteride to protect the hair you still have; what applies to you is your surgeon's and prescriber's call.
Dutasteride requires a prescription and cannot be used without medical supervision.
The one randomised trial and community reports both point to waiting at least 3 to 6 months, and to expecting stabilised shedding rather than regrowth — the published evidence for alfatradiol is a single six-month study in about 100 women.
Yes, low level laser therapy can be safely combined with minoxidil.
TDM-105795 is not sold in any hair product — it is an unapproved experimental compound. The public trial registry shows it has been studied only as a topical scalp solution, in three completed company trials (the largest a 71-participant, 16-week Phase 2); no oral programme is registered, and no peer-reviewed publication exists.
Both men and women benefit from low level laser therapy for hair loss.
No published trial reports when pyrilutamide users first notice a change; its sponsor's studies measured results at 24 weeks, and all of those figures come from company announcements rather than peer-reviewed papers. Pyrilutamide is an unapproved experimental compound.
Applying Estradiol directly to the scalp may help with hormone-related hair thinning.
Aminexil can be a gentle first step before stronger hair loss treatments.
Stemoxydine is a cosmetic ingredient, not an approved hair loss drug, and the manufacturer's three-month trials enrolled men only, reporting a small increase in measured hair density. One small uncontrolled study that included women reported improvement in both sexes but more in men, so a benefit for women is not established.
No published human trial has tested horsetail extract as a treatment for androgenic alopecia; the available evidence is laboratory work and trials of silicon supplements, which point at hair quality rather than at DHT-driven pattern baldness.
The single published fluridil trial (43 men, 9 months, double-blind and placebo-controlled) reported more hairs in the growth phase, but it never measured follicle diameter and has not been replicated — so whether daily use stops miniaturization is unproven, and community users describe stabilization rather than regrowth.
Saw palmetto may help with androgenetic alopecia, not just mild hair loss.
The only human data on Redensyl is a small, unpublished manufacturer study in men who already had androgenetic alopecia; there is no evidence in people without visible hair loss, so nothing supports using it to prevent hair loss before it starts.
SCUBE3 is not currently proven to help with androgenetic alopecia.